480391-86-4

Upstream product

• 43036-14-2 6-methoxy-2-(4-nitrophenyl)benzothiazole 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 6274-29-9 2-amino-5-methoxy-thiophenol 
• 808755-67-1 6-hydroxy-2-bromo-benzothiazole 
• 171364-83-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nitrobenzene 
• 104-94-9 4-methoxy-aniline 
• 73702-95-1 N-(4-methoxyphenyl)-4-nitrothiobenzamide 
• 24730-11-8 N-(4-methoxyphenyl)-4-nitrobenzamide 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 566170-02-3 6-methoxymethoxy-2-(4'-nitrophenyl)-1,3-benzothiazole 
• 949095-70-9 2-(4'-nitrophenyl)-6-(5-bromopentyloxy)benzothiazole 
• 1301256-39-2 2-(4-(N-methyl-N-tert-butoxycarbonylamino)phenyl)benzo[d]thiazol-6-ol 
• 1096700-09-2 C₂₃H₁₉FN₂O₄S 
• 1096700-22-9 C₃₀H₂₆N₂O₅S 
• 566170-03-4 2-(4′-aminophenyl)-6-methoxymethoxybenzothiazole 

Relevant academic research and scientific papers

NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

For nerve degenerative disease is in the field of PET imaging agent precursor and the standard method for the synthesis of (by machine translation)

A novel PET imaging agent precursor and standard and its preparation method, in order to 4-nitro cinnamic aldehyde, the methoxylphenylboronic ethylamine as a reaction initiator, synthesis of the precursor (compound 10) 4 - (6 - (2-P-toluene-sulfonic acid ethoxycarbonyl)-oxy-2-quinolyl)-N-tert-butoxy-carbonyl-N-n-pentyl-( [N-methyl-N-tert-butoxy carbonyl] - 2 - [4 ˊ - (methylamino) phenyl]-benzothiazole aniline) - 6-ether) aniline and standard (compound 25) 4 - (6 - (2-F)-oxy-2-quinolyl)-N-n-pentyl-( [N-methyl] - 2 - [4 ˊ - (methylamino) phenyl]-benzothiazole aniline) - 6-ether) aniline, at the same time provides A β protein specific binding agent 11 C-6-OH-BTA-1 an important intermediate for preparing (compound 7) method for the preparation of, the preparation method is a brand new synthetic route, step is simple, moderate reaction. (by machine translation)

Synthesis and structure-activity relationships of gadolinium complexes of DO3A-benzothiazole conjugates as potential theranostic agents

The synthesis of two bifunctional chelates, 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) conjugates of benzothiazoles (H3L3a and H3L3b), and the corresponding gadolinium complexes (GdL3a

Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimers disease through Suzuki-Miyaura cross-coupling reactions

In positron emission tomography [11C]PIB, Pittsburgh Compound-B, is currently the most widely used radiopharmaceutical for the early diagnosis of Alzheimer's disease. Synthetic routes for the preparation of the precursor of [11C]PIB are reported in the literature. These strategies require multiple steps and the use of protecting groups. This paper describes a simple one-step synthesis of the precursor of [11C]PIB through a Suzuki-Miyaura coupling reaction using thermal conditions or microwave activation. These methods were successfully applied to the synthesis of various 2-arylbenzothiazole and 2-pyridinylbenzothiazole compounds including [ 18F] precursor derivatives of PIB containing a nitro function.

PET PROBE HAVING ALKOXY GROUP SUBSTITUTED BY FLUORINE AND HYDROXY GROUP

Disclosed are: a PET probe compound having an alkoxy group substituted by a fluorine and a hydroxy group, which is useful for the early diagnosis of a conformational disease; a pharmaceutical composition for the treatment and/or prevention of a conformational disease, which comprises the compound; and others.

Synthesis and evaluation of18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in alzheimer's disease

Imaging agents targeting amyloid β(Aβ) may be useful for early diagnosis and follow-up of treatment of patients with Alzheimer's disease (AD). Three of five tested 2-(4′-fluorophenyl)-1,3-benzothiazoles displayed high binding affinities for Aβ plaques in

Synthesis and biological evaluation of 99mTc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl)benzothiazole as potential probes for β-amyloid plaques in the brain

The benzothiazole aniline (BTA) conjugated with monoamine-monoamide (MAMA) was synthesized and then labeled with 99mTc. Its corresponding rhenium analogue was synthesized, and the fluorescent staining was performed in brain sections of both Tg

In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein

An amyloid deposit can be detected by administering to a subject or applying to a sample a compound of Formula (I) or Formula (II) or structures 1-45, as described, and then imaging to detect binding of the compound to an amyloid deposit, where the amyloi

Compounds and amyloid probes thereof for therapeutic and imaging uses

The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the

AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES

The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at lea